Adeona to Host Third Quarter 2010 Investor Conference Call

-- Conference Call Scheduled for Monday, November 15, 2010 at 12:00 Noon EST --

ANN ARBOR, Mich., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its third quarter 2010 investor conference call on Monday, November 15, 2010 at 12:00 Noon EST. James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer, will host the call.

In order to participate in the conference call, please call: United States toll free: 1-800-860-2442 and International dial-in: 1-412-858-4600. To ensure each participant is able to hear the conference call in its entirety, it is recommended that participants dial into the conference line 5 minutes prior to the call. The audio recording will be available for replay at www.adeonapharma.com for a period of at least 30 days after the call.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona has the following product candidates in development: a prescription medical food for Alzheimer's disease, and four drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and dry age-related macular degeneration. For more information, please visit Adeona's website at www.adeonapharma.com.

SOURCE Adeona Pharmaceuticals, Inc.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.